alexa Development Of Innovative Vaccines By The Combination Of Novel Technologies
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Fumihiko Takeshita
Daiichi Sankyo Co. Ltd., Japan
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-057
Abstract
In recent years, outbreaks of infectious diseases such as Ebora hemorrhagic fever and Zika virus-associated neurological diseases have been posing global health concerns worldwide, leading to an increase of public awareness and perceptions of importance of prophylactic vaccines to prevent infectious diseases. Recent progresses in science and technology in the field of vaccine have provided us with opportunities to develop novel vaccines based on such innovations. In this session, the topic is focused on the introduction of novel vaccine technologies currently under development in our company, such as the intradermal (ID) delivery system and a novel adjuvant. With regard to the ID delivery system, which has been co-developed with TERUMO Co. Ltd., the perpendicular insertion of the very tiny needle with 1.15 mm in length and 33G in size can be achieved by specific devices. Results in clinical trials conducted for the new ID vaccine for seasonal flu have demonstrated that more than 98% out of almost 1,000 injections resulted in the wheal formation at injection sites, indicating the accurate and consistent injection into the dermis by this system. Results in non-clinical pharmacology studies for the RSV vaccine candidate have suggested advantages of ID administration and our novel adjuvant in immunogenicity, i.e., both antibody responses and cell-mediated immune responses, and inhibition of allergic responses specific to vaccine antigens. We hope that the combinatorial use of such technologies confers the realization of innovative vaccines such as that targeting respiratory syncytial virus (RSV), which is currently unavailable due to several critical issues hardly overcome by conventional vaccine technologies.
Biography

Fumihiko Takeshita has his expertise in Vaccine R&D in both academia and industry. Based on his experiences in basic research on innate immunity and mechanisms in immunologic pathways in intradermal delivery of antigens and adjuvants, he is leading several different R&D teams of vaccines based on the open innovation network.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords